Join the Liraglutide group to help and get support from people like you.
Liraglutide News (Page 2)
FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes
December 23, 2024 – Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1)...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
FRIDAY, Nov. 22, 2024 – Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
THURSDAY, Nov. 14, 2024 – For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE),...
Ozempic Could Help Curb Alcoholism
WEDNESDAY, Nov. 13, 2024 – The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...
Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
FRIDAY, Sept. 13, 2024 – For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication, and...
Liraglutide Efficacious, Safe for Children Aged 6 to
THURSDAY, Sept. 12, 2024 – Liraglutide plus lifestyle intervention is efficacious for children aged 6 to
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Diabetes, Type 2